We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
-10.26%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$1.22B
AUM Growth
-$279M
Cap. Flow
-$17.4M
Cap. Flow %
-1.42%
Top 10 Hldgs %
79.8%
Holding
47
New
8
Increased
5
Reduced
10
Closed
3

Top Buys

Rank Stock Value
1
MAZE
Maze Therapeutics
MAZE
+$11.4M
2
ONC
BeOne Medicines Ltd
ONC
+$9.35M
3
GEHC icon
GE HealthCare
GEHC
+$8.59M
4
HIMS icon
Hims & Hers Health
HIMS
+$7.43M
5
LAB icon
Standard BioTools
LAB
+$6.77M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$18.2M
2
ILMN icon
Illumina
ILMN
+$16.8M
3
EXAS
Exact Sciences
EXAS
+$12.4M
4
FDMT icon
4D Molecular Therapeutics
FDMT
+$6.41M
5
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$5.14M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AGIO icon
26
Agios Pharmaceuticals
AGIO
$1.82B
$7.33M 0.6%
250,000
– –
MRNA icon
27
Moderna
MRNA
$21.9B
$6.38M 0.52%
225,000
+50,000
+29% +$1.77M
HIMS icon
28
Hims & Hers Health
HIMS
$7.13B
$5.91M 0.48%
+200,000
New +$7.43M
TNYA icon
29
Tenaya Therapeutics
TNYA
$158M
$3.84M 0.31%
6,732,971
– –
VSTM icon
30
Verastem
VSTM
$500M
$3.62M 0.3%
+600,000
New +$3.67M
SEPN
31
Septerna Inc
SEPN
$1.58B
$3.2M 0.26%
553,268
– –
SLDB icon
32
Solid Biosciences
SLDB
$790M
$2.87M 0.23%
+775,000
New +$3.32M
ABSI icon
33
Absci
ABSI
$1.35B
$2.44M 0.2%
973,260
– –
TDOC icon
34
Teladoc Health
TDOC
$1.21B
$2.39M 0.2%
+300,000
New +$3.03M
IPSC icon
35
Century Therapeutics
IPSC
$357M
$1.53M 0.12%
3,212,316
-1,978,190
-38% -$1.49M
DYN icon
36
Dyne Therapeutics
DYN
$4.71B
$1.05M 0.09%
+100,000
New +$1.43M
CTNM
37
Contineum Therapeutics
CTNM
$599M
$1.04M 0.08%
148,333
-148,333
-50% -$1.35M
RXRX icon
38
Recursion Pharmaceuticals
RXRX
$1.69B
$875K 0.07%
165,323
– –
PACB icon
39
Pacific Biosciences
PACB
$441M
$854K 0.07%
723,767
-312,092
-30% -$479K
PRME icon
40
Prime Medicine
PRME
$508M
$731K 0.06%
367,175
– –
GLUE icon
41
Monte Rosa Therapeutics
GLUE
$1.3B
$399K 0.03%
86,014
– –
DNA icon
42
Ginkgo Bioworks
DNA
$584M
$208K 0.02%
36,493
– –
TNGX icon
43
Tango Therapeutics
TNGX
$4.43B
$171K 0.01%
125,000
-1,063,349
-89% -$2.61M
KRON
44
DELISTED
Kronos Bio
KRON
$102K 0.01%
123,839
– –
FDMT icon
45
4D Molecular Therapeutics
FDMT
$527M
– –
-1,150,000
Closed -$6.41M
FTRE icon
46
Fortrea Holdings
FTRE
$1.8B
– –
-275,000
Closed -$5.13M
MRNA icon
47
CALL
Moderna
MRNA
$21.9B
– –
-175,000
Closed -$7.28M
1
2

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
B
BloombergSen Toronto, Ontario, Canada $1.31B AUM 8.32% 1-Year Est. Return
WGAM
Wilkinson Global Asset Management New York $1.31B AUM 17.03% 1-Year Est. Return
CRAM
Compass Rose Asset Management New York $1.33B AUM 2.38% 1-Year Est. Return

Casdin Capital's Q1 2025 Portfolio in Review

As of Q1 2025, Casdin Capital held 47 positions worth $1.22B, down 19% from $1.5B the previous quarter. Its ten largest holdings account for 80% of the portfolio.

Casdin Capital's Q1 2025 filing shows 8 new, 5 increased, 10 reduced and 3 closed positions. Its largest new stake was Maze Therapeutics: 946,357 shares worth $10.4M. The largest sale was Sarepta Therapeutics, an estimated $18.2M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

  • Casdin Capital's largest Q1 2025 buy was Maze Therapeutics: 946,357 shares worth $10.4M.
  • Casdin Capital added most to Standard BioTools in Q1 2025, an estimated $6.77M increase.
  • Casdin Capital's biggest Q1 2025 reduction was Sarepta Therapeutics, cutting an estimated $18.2M.
  • Casdin Capital fully exited 4D Molecular Therapeutics in Q1 2025, selling an estimated $6.41M.
  • Casdin Capital's ten largest holdings make up 80% of its $1.22B portfolio in Q1 2025.
  • Casdin Capital opened 8 new positions and closed 3 in Q1 2025.
  • Casdin Capital's portfolio value fell 19% quarter-over-quarter to $1.22B.

Based on Casdin Capital's 13F filing for Q1 2025, filed 15 May 2025.